Skip to content

Study · Non-randomized trial · n = 11 · 1989

10 results

A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata.

Schlaff WD, Zerhouni EA, Huth JA, Chen J, Damewood MD, Rock JA

Obstetrics and gynecology1 Dec 1989Cited by 61 (Europe PMC)

PMID2511532 (opens in a new tab)PepBankPUB-02511532
Publisher pageAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, all three measured uterine volumes decreased after leuprolide versus pre-therapy (P less than .02).

    In plain wordsIn women with fibroids, total uterine, fibroid and non-fibroid volumes decreased after leuprolide compared with before treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseTotal uterine, myoma and non-myoma volumes
    Study

    n = 11

    Comparator
    Pre-therapy
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Pre- versus post-therapy values for all 11 patients showed significant reduction in all three volumes (P less than .02).
    3 context sentences
    Summary · context
    Magnetic resonance imaging was used to identify specifically the total uterine volume, total myoma volume, and total non-myoma volume.
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, leuprolide significantly reduced total uterine volume compared with placebo.

    In plain wordsIn women with fibroids, leuprolide reduced total uterine volume more than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseTotal uterine volume versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Treated patients had a significant reduction in total uterine and non-myoma volumes as compared with placebo patients (P less than .02).
    2 context sentences
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, leuprolide significantly reduced non-myoma volume compared with placebo.

    In plain wordsIn women with fibroids, leuprolide reduced non-fibroid uterine volume more than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseNon-myoma volume versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Treated patients had a significant reduction in total uterine and non-myoma volumes as compared with placebo patients (P less than .02).
    2 context sentences
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, myoma volume decreased with leuprolide versus placebo, with P = .06.

    In plain wordsIn women with fibroids, fibroid volume decreased with leuprolide versus placebo, with P = .06.

    Peptide
    Leuprolide
    Outcome
    DecreaseMyoma volume versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Total myoma volume was also reduced, but only to a P = .06 level.
    3 context sentences
    Summary · context
    Treated patients had a significant reduction in total uterine and non-myoma volumes as compared with placebo patients (P less than .02).
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, most symptoms improved markedly during leuprolide treatment.

    In plain wordsIn women with fibroids, most symptoms improved markedly during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedSymptoms
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Overall treatment effect · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Most symptoms were markedly improved.
    2 context sentences
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, all three measured uterine volumes returned to baseline by 24 weeks after leuprolide therapy.

    In plain wordsIn women with fibroids, total uterine, fibroid and non-fibroid volumes returned to baseline by 24 weeks after leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedTotal uterine, myoma and non-myoma volumes after therapy
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    By 24 weeks post-therapy, all volumes had returned to baseline levels, although symptomatic improvement commonly persisted.
    3 context sentences
    Summary · context
    Magnetic resonance imaging was used to identify specifically the total uterine volume, total myoma volume, and total non-myoma volume.
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, symptomatic improvement commonly persisted at 24 weeks after leuprolide therapy.

    In plain wordsIn women with fibroids, symptom improvement commonly persisted at 24 weeks after leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedPersistent symptom improvement
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Overall treatment effect · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    By 24 weeks post-therapy, all volumes had returned to baseline levels, although symptomatic improvement commonly persisted.
    2 context sentences
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.
  8. 08HumanNon-randomized trialEfficacy outcome

    In women with leiomyomata, leuprolide reduced non-myoma volume proportionally more than myoma volume, 42.7 versus 30.4%.

    In plain wordsIn women with fibroids, non-fibroid volume decreased more than fibroid volume during leuprolide treatment, 42.7 versus 30.4%.

    Peptide
    Leuprolide
    Outcome
    IncreaseProportional volume reduction
    Study

    n: not reported in source

    Comparator
    Myoma volume reduction
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Volume reduction
    42.7%
    non-myoma
    Volume reduction
    30.4%
    myoma

    Source sentences

    Summary
    The non-myoma volume was proportionally reduced to a greater extent than the myoma volume (42.7 versus 30.4%), and we therefore could explain the reenlargement seen when treatment was discontinued.
    2 context sentences
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.
  9. 09HumanNon-randomized trialSafety outcome

    In women with leiomyomata, leuprolide side effects were well tolerated.

    In plain wordsIn women with fibroids, leuprolide side effects were well tolerated.

    Peptide
    Leuprolide
    Outcome
    Not applicableSide-effect tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Side effects were well tolerated and there were no study dropouts.
    2 context sentences
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.
  10. 10HumanNon-randomized trialSafety outcome

    In the leuprolide study in women with leiomyomata, no study dropouts occurred.

    In plain wordsIn the leuprolide study in women with fibroids, no participants left the study.

    Peptide
    Leuprolide
    Outcome
    Not applicableStudy dropouts
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Side effects were well tolerated and there were no study dropouts.
    2 context sentences
    Summary · context
    We performed a double-blind, placebo-controlled study of a depot form of a GnRH analogue (leuprolide) given monthly for 24 weeks in 11 patients with symptomatic uterine leiomyomata.
    Summary · context
    Patients initially treated with placebo were subsequently treated with active drug for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.